521 completed, 199 recruiting, 153 unknown, 93 active not recruiting. 287 Phase 2, 248 Not applicable, 217 Phase 1, 134 Phase 3, 49 Phase 4.
Follow Eye Diseases, Hereditary: new trials by email Literature Review of Eye Diseases, Hereditary trials Research Report on Eye Diseases, Hereditary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease MHB018A injection - Thyroid Eye Disease (TED) | Phase 3 | Not yet recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 219 | 2027-07-01 | 2026-06-04 |
| Non-invasive Ultrasound Retinal Stimulation for Vision Restoration Non-invasive ultrasound retinal stimulation Device - Age-Related Macular Degeneration, Retinitis Pigmentosa | Not applicable | Not yet recruiting | University of Southern California | 5 | 2027-01-10 | 2026-01-08 |
| 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome N-acetylcysteine amide, Placebo - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Not yet recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-12-01 | 2026-07-01 |
| Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department Haloperidol - Cannabinoid Hyperemesis Syndrome | Early Phase 1 | Not yet recruiting | University of Illinois at Chicago | 100 | 2026-11-01 | 2026-09-01 |
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| Transconjunctival Versus Transcutaneous Betamethasone for Upper Eyelid Retraction in TED Betamethasone - Thyroid Eye Disease | Not applicable | Not yet recruiting | Assiut University | 54 | 2026-10-10 | 2026-10-08 |
| Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Not yet recruiting | Laboratoires Thea | 81 | 2026-10-05 | 2026-09-01 |
| Retinal and Choroidal Changes in Periodontal Disease Periodontal Diseases, Periodontal Diseases Inflammation | Not yet recruiting | Zeliha Başak Çakır Erdil | 80 | 2026-10-01 | 2026-10-05 | |
| Partial Range Of Field IOLs in DMEK-Enabled Procedures combined cataract and lamellar endothelial keratoplasty - Cataract, Fuchs Endothelial Corneal Dystrophy | Not applicable | Not yet recruiting | Universitair Ziekenhuis Brussel | 10 | 2026-10-01 | 2026-08-25 |
| Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy GEB-101 Injection - Hereditary Corneal Dystrophy, Corneal Abnormality | Phase 1 / Phase 2 | Not yet recruiting | GenEditBio Limited | 30 | 2026-10-01 | 2026-09-10 |
| A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome Placebo, NPI-001 - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-10-01 | 2026-10-13 |
| Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction 150K cells, 500K cells, Placebo - Corneal Edema, Fuchs | Phase 2 | Recruiting | Emmecell | 121 | 2026-10-01 | 2026-10-09 |
| Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa ULREA-PVS-NP - Retinitis Pigmentosa (RP) | Phase 1 | Recruiting | Kyushu University | 21 | 2026-10-01 | 2026-10-07 |
| Phase I/II Open-Label Trial of UGX202 for Advanced Retinitis Pigmentosa UGX202 Injection - Retinitis Pigmentosa (RP) | Phase 1 | Not yet recruiting | Suzhou UgeneX Therapeutics Co., Ltd. | 12 | 2026-09-28 | 2026-10-02 |
| Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study MHB018A, MHB018A placebo - Thyroid Eye Disease, TED | Phase 3 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 84 | 2026-09-28 | 2026-10-14 |
| Treatment of Chronic Thyroid Eye Disease With MHB018A MHB018A injection, MHB018A injection Placebo - Thyroid Eye Disease, TED | Phase 3 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 135 | 2026-09-24 | 2026-10-14 |
| Natural History Study of Advanced RCD Eye examinations, Questionnaire - Rod Cone Dystrophy | Not applicable | Recruiting | SparingVision | 100 | 2026-09-11 | 2026-10-08 |
| An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab veligrotrug (LUMVOA™) - Thyroid Eye Disease | Phase 4 | Not yet recruiting | Viridian Therapeutics, Inc. | 30 | 2026-09-01 | 2026-09-21 |
| Topical CBD Scar Outcomes Study Group 1 cannabidiol (CBD) with silicone ointment, Group 2 silicone patch - Forehead; Wound | Early Phase 1 | Not yet recruiting | University of Oklahoma | 22 | 2026-09-01 | 2026-04-01 |
| A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants CITY-RBP4, Placebo - Stargardt Disease 1, STGD1 | Phase 1 | Recruiting | City Therapeutics | 48 | 2026-09-01 | 2026-09-23 |
Showing 20 of 1164. Sign in to see all of them.
Retinitis Pigmentosa (267) · Graves Ophthalmopathy (197) · Retinal Degeneration (130) · Retinoblastoma (117) · Eye Diseases (100) · Retinal Diseases (96) · Fuchs' Endothelial Dystrophy (92) · Macular Degeneration (86) · Stargardt Disease (66) · Color Vision Defects (62) · Optic Atrophy, Hereditary, Leber (44) · Vision Disorders (40) · Cone-Rod Dystrophies (39) · Graves Disease (36)
Eye Diseases (1047) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (916) · Genetic Diseases, Inborn (887) · Retinal Diseases (490) · Retinal Degeneration (312) · Nervous System Diseases (298) · Retinal Dystrophies (273) · Endocrine System Diseases (253) · Pathological Conditions, Signs and Symptoms (248) · Immune System Diseases (236) · Autoimmune Diseases (202) · Goiter (195) · Orbital Diseases (193) · Signs and Symptoms (192)
Carboplatin (26) · Etoposide (24) · Methylprednisolone (23) · Melphalan (18) · Vincristine (18) · Filgrastim (15) · aflibercept (15) · teprotumumab (15) · salicylhydroxamic acid (14) · Cyclophosphamide (13) · Topotecan (11) · Granulocyte Colony-Stimulating Factor (10) · Blood Specimen Collection (9) · Ophthalmic Solutions (9) · Ranibizumab (9)
National Eye Institute (NEI) (34) · Sun Yat-sen University (26) · Amgen (16) · Johns Hopkins University (16) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (13) · Beacon Therapeutics (11) · University of Pisa (11) · Memorial Sloan Kettering Cancer Center (10) · St. Jude Children's Research Hospital (10) · GenSight Biologics (9) · National Human Genome Research Institute (NHGRI) (9) · Viridian Therapeutics, Inc. (9) · Columbia University (8) · Laboratoires Thea (8) · MeiraGTx UK II Ltd (8)
United States (538) · France (143) · Germany (119) · United Kingdom (118) · China (110) · Canada (73) · Italy (70) · Spain (60) · Netherlands (54) · Australia (49) · Poland (32) · Israel (30) · Belgium (28) · Brazil (27) · Denmark (23)
Brian P Brooks, M.D. (8) · Pablo Velazquez-Martin, MD (7) · Francis W Price, Jr, MD (5) · Carlos Rodriguez-Galindo, MD (4) · Dan Liang (4) · Dan Liang, MD (4) · David Meeker, MD (4) · Jennifer Henrick, RN, MS (4) · Mohamed Genead, MD (4) · Umut Arslan, MD (4)
PMID 30194931, PMID 32573764, PMID 40547876, PMID 36449262, PMID 34108929, PMID 23049090, PMID 37261916, PMID 37314061, PMID 38254722, PMID 17102659, PMID 18441370, PMID 18441371, PMID 18774912, PMID 19953081, PMID 21606598, PMID 22281388, PMID 22323828, PMID 22562517, PMID 22761263, PMID 23668681, PMID 24150759, PMID 25458728, PMID 25812924, PMID 26199618, PMID 26604914, PMID 26606867, PMID 26892229, PMID 27857759, PMID 27904503, PMID 28878616, PMID 29445374, PMID 29940167, PMID 30369044, PMID 31215818, PMID 31401903, PMID 32131056, PMID 32303913, PMID 32343050, PMID 32787913, PMID 33591032, PMID 33768488, PMID 34633355, PMID 35814763, PMID 39207600, PMID 41066062, PMID 41126474, PMID 10511047, PMID 10548467, PMID 10634372, PMID 10656302
2017 (11), 2016 (7), 2018 (7), 2023 (7), 2015 (6), 2009 (3), 2019 (3), 2025 (3), U10CA098543 (3), 2014 (2), P01CA023099 (2), P30CA008748 (2), P30CA021765 (2), R24EY022023 (2), 1UG1EY030030-01A1 (1)